June 19, 2020
SUZHOU, China, June 19, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today...
Source URL: https://www.prnewswire.com:443/news-releases/innovent-announces-the-nmpa-granted-marketing-approval-for-byvasda-bevacizumab-biosimilar-in-china-301080076.html
|
